Which Crowdfunding Platforms Grew the Fastest in 2025?

CHART OF THE WEEK

Which crowdfunding platforms are actually gaining momentum? This week’s chart looks at year-over-year growth from 2024 to 2025, highlighting where capital is flowing fastest. The results show a mix of breakout performances driven by a few large deals and steadier rebounds from established platforms. In today’s market, growth is less about volume—and more about trust, timing, and attracting the right campaigns.

Have a suggestion for a data story you’d like us to look into? Submit by replying to this email.

EVENTS

Investment Crowdfunding Week returns April 13–15 with Tim Draper opening the conversation on the future of private markets, investor fireside sessions on alternative assets, the creator economy, and deal evaluation, plus 20 Kingscrowd-vetted companies pitching live — register free and vote to crown the $5,000 grand prize winner.

KINGSCROWD PODCAST

From new SEC guidance to emerging investment products, private markets are expanding fast — but not always in ways that make investing easier.

This week on the Kingscrowd Podcast, Brian and Scott break down the latest shifts across equity crowdfunding and alternative assets — from mirror investing and late-stage secondaries to crypto clarity and the shutdown of FranShares.

The takeaway: more access doesn’t always mean better outcomes. As the ecosystem matures, understanding structure, risk, and incentives matters more than ever.

PITCH REVIEW 💸

By Teddy Lyons \ Deal Report

Brief: Frontier Bio focuses on developing implantable human tissues and reducing reliance on animal testing through human tissue models for preclinical research. Its lead product is a tissue-engineered vascular graft, with broader ambitions to address organ shortages and support future therapies. Founded in 2018 by Eric Bennett, Frontier Bio is raising up to $1.24 million to support business development, legal and IP work, and operational expenses.

Teddy’s Quick Take: 

As an active early-stage biotech investor, there is always an elephant in the room when I speak with founders: in order to bring a drug to the market, animals must die.

Sorry if that was brash, but it’s the truth.

In early pre-clinical work, the predominant test subjects are mice. However, the FDA requires safety data from two species. So scientists must then test on animals we’re a little too familiar with: dogs, non-human primates, pigs, and rabbits, among others.

Before you get too sad about this, let me introduce you to Frontier Bio. This company creates lab-grown human tissue models that replicate real organs like the brain, lungs, and blood vessels. Researchers can then use these for drug testing and disease studies instead of animals.

This is not just an idea. The company has already generated $5.5 million in cumulative sales from its tissue models and services, landing contracts from major clients like Mayo Clinic and Intuitive Surgical. They've also secured $4.1 million in prior funding along with NSF SBIR grants.

CEO Eric Bennett is a serial entrepreneur and biomedical engineer who previously designed low-cost 3D bioprinters. CTO Dr. Sam Pashneh-Tala is a recognized expert in tissue-engineered blood vessels with a highly cited review paper in the field. They're advised by synthetic biology pioneer Dr. George Church from Harvard and other top experts from Alchemist Accelerator, UC Berkeley, and Johns Hopkins.

Of course, the use case here is far broader than just eliminating animal trials. The bigger vision is implantable tissues, starting with a vascular graft made from a patient's own stem cells on a bioresorbable scaffold. It integrates naturally in the body, starts working immediately, and could one day lead to full transplantable organs like kidneys or hearts.

VC-backed biotech with $5.5M in commercial revenue, and most importantly, saving animals.

Where do I sign up? 

STAFF PICKS 🌶️

CYBR International

By Léa Bouhelier-Gautreau

CYBR is an AI cybersecurity company raising at a reasonable revenue multiple, with a $16 million valuation on $3.9 million in revenue. But the company is planning to list on NASDAQ in 2027. Will a fair multiple in ECF hold up in the public markets? Will investors see strong returns in less than two years, or could the stock drop after listing?

Azure Printed Homes

By Léa Bouhelier-Gautreau

Azure Printed Homes is back with its seventh equity crowdfunding round in just four years. The company has grown at a stead pace, generating $4.2 million in 2023, $5.1 million in 2024, and reaching a current run rate of $7.6 million. Its core offering stands out for being both more affordable and faster to deliver than competing solutions. The challenge now is execution: to meaningfully accelerate growth and translate that advantage into the kind of scale needed to drive strong investor returns.

Enjoyed this newsletter? Forward it to an investing-minded friend and have them signup here.